GPGrossPatternRESEARCH SYSTEM
SEC CHECK OPERATIONAL
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME

BTAI · Jun 30, 2025

BioXcel Therapeutics, Inc.. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.

STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration

State dimensions

Filing0001558370-25-011158General Corporate
Debt relative to revenueRAWCurrent state valid · history insufficient
Evidence method

Level · gp.fundamentals.debt_to_revenue

90570.83% · OPTIONAL · NOT_ENOUGH_HISTORY

Operating cash generation45thOwn-history percentile · N=11
Evidence method

Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue

-10479.17% · OPTIONAL · VALID

Revenue growthRAWCurrent state valid · history insufficient
Evidence method

Yoy · gp.fundamentals.revenue

-89.13% · CORE · NOT_ENOUGH_HISTORY

Inventory pressure55thOwn-history percentile · N=11
Evidence method

Level · gp.fundamentals.inventory_revenue_ratio

421.67% · OPTIONAL · VALID

Gross margin36thOwn-history percentile · N=11
Evidence method

Level · gp.fundamentals.gross_margin

10.83% · CORE · VALID

Operating margin36thOwn-history percentile · N=11
Evidence method

Level · gp.fundamentals.operating_margin

-13210.00% · CORE · VALID

R&D intensity73thOwn-history percentile · N=11
Evidence method

Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue

8546.67% · OPTIONAL · VALID

SBC intensity55thOwn-history percentile · N=11
Evidence method

Level · gp.fundamentals.sbc_revenue_ratio

1296.67% · OPTIONAL · VALID

As-filed lineage

Fundamental state history

Each observation is tied to the filing and facts available at that report date. Amendments remain separate.

History16 statesHistory building
Sep 30, 20220/7 normalizedLevel 3Dec 31, 20220/7 normalizedLevel 3Mar 31, 20230/6 normalizedLevel 3Jun 30, 20230/6 normalizedLevel 3Sep 30, 20230/8 normalizedLevel 3Dec 31, 20230/8 normalizedLevel 3Mar 31, 20240/7 normalizedLevel 3Jun 30, 20240/7 normalizedLevel 3Sep 30, 20246/7 normalizedLevel 3Dec 31, 20246/7 normalizedLevel 3Mar 31, 20256/8 normalizedLevel 3Jun 30, 20256/8 normalizedLevel 3Sep 30, 20257/9 normalizedLevel 3Dec 31, 20257/9 normalizedLevel 3Mar 31, 20267/9 normalizedLevel 3Jun 30, 20267/9 normalizedLevel 3
Period transition

What moved in the state?

Balance Sheet Leverage Increased
Previous
62813.10%
Current
90570.83%
Delta
27757.74%
Cash Generation Decreased
Previous
-7168.45%
Current
-10479.17%
Delta
-3310.71%
Growth Decreased
Previous
-71.13%
Current
-89.13%
Delta
-18.00%
Inventory Pressure Increased
Previous
382.14%
Current
421.67%
Delta
39.52%
Margin Decreased
Previous
91.67%
Current
10.83%
Delta
-80.83%
Profitability Decreased
Previous
-6011.31%
Current
-13210.00%
Delta
-7198.69%
R And D Intensity Increased
Previous
2710.71%
Current
8546.67%
Delta
5835.95%
Sbc Intensity Increased
Previous
107.14%
Current
1296.67%
Delta
1189.52%
Self-history only

Previous similar states

Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.

Not enough compatible prior states for a transparent self-history match.
Research Graph

Related governed research

Transitioned To · BTAI Fundamental State →Transitioned To · BTAI Fundamental State →Transitioned To · BTAI BALANCE_SHEET_LEVERAGE_INCREASED →Transitioned To · BTAI CASH_GENERATION_DECREASED →Transitioned To · BTAI GROWTH_DECREASED →Transitioned To · BTAI INVENTORY_PRESSURE_INCREASED →Transitioned To · BTAI MARGIN_DECREASED →Transitioned To · BTAI PROFITABILITY_DECREASED →Transitioned To · BTAI R_AND_D_INTENSITY_INCREASED →Transitioned To · BTAI SBC_INTENSITY_INCREASED →

Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.